Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Longer treatment duration, using semaglutide, higher percentage body fat, and nondiabetic status may be associated with better weight reduction.

GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...

Individuals with type 2 diabetes who receive treatment with GLP-1 RAs do not have an increased risk for acute pancreatitis.

Findings of study demonstrating the effectiveness of combining bimagrumab – a drug designed to combat muscle loss – with a common GLP-1 receptor agonist (RA), semaglutide, were presented ...

Hims & Hers is pitching consumers on a GLP-1 weight loss injection that will cost 85% less than brand-name drugs like Wegovy.

While Kanzen Meal’s products were formulated with GLP-1 users in mind, the brand’s marketing appeals to a broader consumer set focused on nutrient density but also great taste.

About BMF-650 BMF-650 is an investigational, next-generation oral small-molecule GLP-1 RA being developed by Biomea Fusion for the treatment of obesity.

In rodent studies, GLP-1 receptors have also been detected on parafollicular thyroid C cells, which are activated with GLP1-RA as evidenced by increased calcitonin secretion.

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased ...